Table 1.

Emerging drugs in the treatment of nonalcoholic fatty liver disease (NAFLD). FXR: farnesoid X receptor; PPAR: peroxisome proliferator-activated receptor; CCR: C-C chemokine receptor; FGF: fibroblast growth factor; TLR: toll-like receptor; NCT: National Clinical Trial.

	Drug Therapy	Current Clinical Trial Name	Phase	Mechanism of Action
1	Obeticholic Acid	REGENERATE; NCT02548351 [21]	3	FXR agonist
2	GS-9674	NCT02854605 [23]	2	FXR agonist
3	Elafibranor	RESOLVE-IT, NCT02704403 [28]	3	Dual PPAR α/δ agonist
4	Cencriviroc	AURORA; NCT03028740 [36,37]	3	CCR2 and CCR5 dual antagonist
5	GR-MD-02	NASH-CX [42,43]	2b	Galectin-3 inhibitor
6	NGM282	NCT02443116 [50]	2	Variant of FGF19
7	MGL-3196	NDT02912260 [53]	2	Selective thyroid hormone receptor-beta agonist
8	Selonsertib	STELLAR-3; NCT03053050 [8] and STELLAR-4; NCT03053063 [8]	3	Apoptosis signal-regulating kinase 1 inhibitor
9	Simtuzumab	NCT02466516 [62] and NCT01672879 [11]	2, 2b	Monoclonal antibody against LOXL2
10	Selonsertib + Simtuzumab	NCT02466516 [62]	2
11	GS-0976	NCT 02856555 [70]	2	Acetyl-coenzyme A carboxylase (ACC) inhibitor
12	Selonsertib + GS-9674	ATLAS, NCT03449446 [64]	2
13	Selonsertib + GS-0976	ATLAS, NCT03449446 [64]	2
14	JKB-121	NCT02442687 [71]	2a	TLR-4 antagonist
15	SGM-1019	NCT	2a	Inflammasome inhibitor
16	BMS-986036		2a	Pegylated fibroblast growth factor 21 (FGF21) analogue [76,77]
17	Aramchol		2b	Synthetic fatty acid/bile acid conjugate [76,77]
18	Volixibet		2a	Apical sodium dependent bile acid transporter inhibitor [76,77]
19	LMB763		2a	FXR agonist [76,77]
20	LJN452		2a	FXR agonist [76,77]
21	Emricasan		2b	Oral caspase inhibitor [76,77]
22	Saroglitazar		2a	PPAR α/δ agonist [76,77]
23	IVA337		2a	Pan-PPAR agonist [76,77]
24	IMM-124E-Hyperimmune bovine colostrum		2a	Induction of regulatory T-cells [76,77]
25	BI-1467335		2a	Amino-oxidase copper (AOC) containing-3 inhibitor [76,77]
26	LIK066		2a	Sodium glucose cotransporter inhibitor (SGLT) [77]